2025-10-17 - Analysis Report
Okay, here's an analysis of Tempus AI Inc. (TEM) based on the data provided, presented with numbers first, followed by analysis and commentary.

## Tempus AI Inc. (TEM) Analysis

Tempus AI Inc. is a technology company that provides data-driven precision medicine to help personalize healthcare through data and AI.

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 43.99%
*   **VOO Cumulative Return:** 25.65%
*   **Absolute Divergence (TEM - VOO):** 18.34%
*   **Divergence Range:** Max 74.4, Min -40.6
*   **Relative Divergence:** 60.3

**Analysis:** TEM has significantly outperformed the S&P 500 (VOO) since its IPO.  The relative divergence of 60.3 indicates that TEM's outperformance is in the upper-middle range of its historical divergence from the index.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2023-2025  | 44.0% | 70.1% | 19.0% | 0.3  | 15.8   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  A high CAGR of 44% suggests strong growth.
*   **MDD (Maximum Drawdown):** A very high MDD of 70.1% indicates significant volatility and risk.
*   **Alpha:** The positive alpha (19.0%) confirms TEM's outperformance relative to its risk level.
*   **Beta:** A low beta (0.3) suggests that TEM is less sensitive to overall market movements (S&P 500).
*   **Cap:** $15.8 billion market capitalization

### 2. Recent Stock Price Action

*   **Current Price:** 89.87
*   **Last Market Data:** {'price': 91.02, 'previousClose': 91.91, 'change': -0.97}
*   **5-day Moving Average:** 96.39
*   **20-day Moving Average:** 88.04
*   **60-day Moving Average:** 76.54

**Analysis:** The current price is below the 5-day moving average, but above the 20-day and 60-day moving averages. This suggests a potential short-term downtrend, but the price is still supported by longer-term trends. The last market data {'price': 91.02, 'previousClose': 91.91, 'change': -0.97} indicates a slight decline in the most recent trading session.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 62.87
*   **PPO:** 0.0822
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change (20-day):** 11.4 (+) - Short-term increase
*   **Expected Return:** NaN

**Analysis:**

*   **MRI:** A value of 0.8 suggests a medium level of investment recommendation based on risk.
*   **RSI:** The RSI of 62.87 is approaching overbought territory (typically above 70), but is not there yet.
*   **PPO:** The PPO (Percentage Price Oscillator) is positive, suggesting that the shorter-term moving average is above the longer-term moving average, indicating an upward trend.
*   **Hybrid Signal:** Recommends buying 100% of available cash in TEM.
*   **Recent Relative Divergence:** A 11.4 (+) increase in the recent relative divergence indicates positive short-term momentum and potential for further gains.
*   **Expected Return:** The "NaN" value for expected return is unhelpful - likely indicating insufficient data for calculation. The slight decline in the most recent trading session {'price': 91.02, 'previousClose': 91.91, 'change': -0.97} doesn't indicate a significant issue.

### 4. Recent News & Significant Events

*   **Collaborations:** Tempus is actively forming collaborations with companies like Whitehawk Therapeutics to advance oncology research.
*   **Conference Presentations:** Tempus is presenting research at major medical conferences, indicating active engagement in the scientific community.
*   **ARPA-H Program:** Tempus has secured a significant role in the ARPA-H Adaptive Cancer Program.
*   **Bull Case Theory:** At least one analyst outlet (Insider Monkey) has presented a bullish case for Tempus.

**Analysis:** The news flow is overwhelmingly positive. Collaborations, conference presentations, and participation in the ARPA-H program all point to a company actively developing and deploying its technology. The "Bull Case Theory" article suggests potential upside based on the company's fundamentals.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean Rating: 2.15)
*   **Opinions:** 11 Analysts
*   **Target Price (avg/high/low):** 77.55 / 100.00 / 60.00

**Analysis:** The analyst consensus is a "Buy" with an average target price of $77.55. The current price of $89.87 is above the average target price, suggesting the stock may be currently trading at a premium to its perceived value by analysts, but the high target of $100 indicates some analysts see further upside potential.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:** Tempus AI is not yet profitable.  The EPS (Earnings Per Share) is consistently negative. However, in most recent quarters, the actual EPS has been *better* than the expected EPS, indicating the company is managing expectations and showing improvements in profitability, except 2025-02-24.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.31B  | 61.99%        |
| 2025-03-31   | $0.26B  | 60.69%        |
| 2024-12-31   | $0.20B  | 60.83%        |
| 2024-09-30   | $0.18B  | 58.50%        |
| 2024-06-30   | $0.17B  | 45.50%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE        |
|--------------|---------|------------|
| 2025-06-30   | $0.31B  | -13.84%    |
| 2025-03-31   | $0.33B  | -20.86%    |
| 2024-12-31   | $0.06B  | -23.10%    |
| 2024-09-30   | $0.05B  | -141.16%   |
| 2024-06-30   | $0.10B  | -562.04%   |

**Analysis:**

*   **Revenue:**  Revenue is growing consistently, indicating increasing demand for Tempus's services.
*   **Profit Margin:** Profit margins are very high (above 60%), which is a positive sign.
*   **Equity:** Equity has fluctuated, possibly due to funding rounds or operational results.
*   **ROE (Return on Equity):** The ROE is negative, consistent with the negative EPS. However, it is trending towards less negative, indicating improvements.

### 7. Overall Assessment

Tempus AI (TEM) is a high-growth, but currently unprofitable, company in the precision medicine space. The company has outperformed the S&P 500 since its IPO, but exhibits significant volatility.

**Positives:**

*   **Strong Revenue Growth:**  Revenue is consistently increasing.
*   **High Profit Margins:**  The company generates impressive profit margins.
*   **Positive News Flow:**  Collaborations, conference presentations, and ARPA-H participation are all strong indicators.
*   **Analyst Consensus:**  Generally positive, with a "Buy" rating.
*   **Technical Indicators:** Show positive momentum.
*   **Hybrid Signal:** Suggests buying.

**Negatives:**

*   **Unprofitable:**  The company is not yet profitable, leading to negative EPS and ROE.
*   **High Volatility:**  The large MDD indicates significant price swings.
*   **Premium Valuation:** The current price is trading above the average analyst target.
*   **High Risk:** High MDD, negative ROE, and recent IPO requires high caution.

**Conclusion:**

Tempus AI presents a compelling, but high-risk, investment opportunity.  The company's strong revenue growth, high profit margins, and positive news flow suggest a promising future. However, the lack of profitability and high volatility are significant concerns.  Investors should carefully consider their risk tolerance and investment horizon before investing in TEM.

**Disclaimer:** This analysis is based solely on the information provided and should not be considered financial advice. Consult with a qualified financial advisor before making any investment decisions.
